DKK1 and Alzheimer disease: To assess the Wnt signaling responsiveness, differentiated AD-NLCs were treated with canonical Wnt agonist (Wnt3a)/Wnt antagonist (Dkk-1) or noncanonical ligand (Wnt5a) for 24 h before adding hRenin as previously: p-JNK and translocation of β-catenin into the nucleus was evaluated.